Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by E. Makarova
Prs48 - Cost – Effectiveness Analysis of Vilanterol/Fluticasone Furoate for Asthma Treatment in the Russian Federation
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Prs38 - Cost-Consequence Analysis of Fluticasone Furoate/Vilanterol for Asthma Management in Spain: An Analysis Based on the Salford Lung Study in Asthma
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost–consequence Analysis of Fluticasone Furoate/Vilanterol 92/22 MCG for the Management of COPD in the Spanish NHS
ClinicoEconomics and Outcomes Research
Health Policy
Economics
Econometrics
Finance
Integrated Safety and Efficacy Analysis of Once-Daily Fluticasone Furoate for the Treatment of Asthma
Respiratory Research
Pulmonary
Respiratory Medicine
Once-Daily Fluticasone Furoate/Vilanterol Combination Versus Twice-Daily Budesonide/Formoterol Combination in the Treatment of Controlled Stable Asthma: A Randomized Crossover Trial
Journal of Asthma and Allergy
Immunology
Pulmonary
Allergy
Respiratory Medicine
Fluticasone Furoate: Once-Daily Evening Treatment Versus Twice-Daily Treatment in Moderate Asthma
Respiratory Research
Pulmonary
Respiratory Medicine
Reduction in All-Cause Mortality With Fluticasone Furoate/Umeclidinium/Vilanterol in COPD Patients
American Journal of Respiratory and Critical Care Medicine
Pulmonary
Critical Care
Respiratory Medicine
Intensive Care Medicine
Prs50 - Cost-Effectiveness Analysis of Surfactant Therapy for the Treatment of Respiratory Distress Syndrome Newborn in the Russian Federation
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Fluticasone Furoate/Vilanterol Once Daily Improves Night-Time Awakenings in Asthma Patients With Night Symptoms; Post-Hoc Analyses of Three Randomized Controlled Trials
Journal of Asthma
Child Health
Allergy
Perinatology
Immunology
Medicine
Pediatrics
Pulmonary
Respiratory Medicine
Human Medicines European Public Assessment Report (EPAR): Revinty Ellipta, Fluticasone Furoate / Vilanterol, Asthma, Date of Authorisation: 02/05/2014, Revision: 16, Status: Authorised
Case Medical Research
